Articles

Dealing countefeit and unapproved medicines is a serious offence as shown in recent TGA prosecution outcome in South Australia

Is there a hangover cure? Essential reading for anyone visited by spirits these holidays.

Infliximab and mycosis fungoides, infliximab and lupus-like syndrome, and medicine shortages mandatory reporting

This legal action follows an investigation by the Therapeutic Goods Administration

TGO 100 has been registered on the Federal Register of Legislation. It commences on 8 December 2018, repealing and replacing TGO 98

There will not be a decision announced on scheduling of alkyl nitrites on 29 November 2018. Further public consultation will be undertaken.

Reforms relating to accessing unapproved products include modifications to the Special Access Scheme and Authorised Prescriber scheme to allow streamlined access to certain unapproved therapeutic products.

The complementary medicine regulatory reforms include changes that will create a new approval pathway for listed complementary medicines and increase availability of information to support consumer decisions.

The prescription medicines regulatory reforms include changes that will bring medicines to market sooner in Australia, while maintaining a robust framework for safety, quality and efficacy.

Reforms to TGA advisory committees include changes that provide greater efficiencies and a reduction in the number of statutory advisory committees that provide independent advice to the TGA.

Standards minimise risk of misconnections; eltrombopag interference with test results; amniotic fluid tests

Cabozantinib (CABOMETYX) is the first medicine to be registered via the new COR-A pathway

What is the TGA?  Learn why and how we regulate medicines and medical devices. 

Joint media release between Australian Border Force and Therapeutic Goods Administration

Some retailers try to use disclaimers like 'for research purposes only' to sell an illegal product, but these disclaimers don't change the law.

Case studies in Incident Report Investigations; review of reusable biopsy forceps devices; care required with patient lifters

The TGA has launched a web hub to help consumers and health professionals find information on transvaginal (urogynaecological) surgical mesh.

New warning labels for neuromuscular blocking agents; local anaesthetic systemic toxicity; off-label use of atropine

Georgia's story explains how to spot the warning signs for the breast implant associated cancer BIA-ALCL.

TGA issues advertising direction

Today we celebrate the official launch of the TGA Facebook page

The TGA completed a desktop review of selected listed sunscreen products.

Be aware of cross-reactivity with home-use self-test ovulation kits, TGA undertakes product safety review into intragastric balloon systems

Our annual survey measures satisfaction with a range of services and activities including our role and performance

Apalutamide (Erlyand) is the first medicine approved via ACSS Consortium’s NCE working group